- Disc sets up polycythemia vera challenge but Silence maintains leadThe polycythemia vera field is heating up, with Disc Medicine and Silence Therapeutics each advancing next-generation therapies, playing catch-up to Takeda and Protagonist Therapeutics, who won the…
- Molecular residual disease testing offers earlier insight into cancer treatment responseIn oncology, determining whether cancer has truly been eliminated after therapy is challenging because imaging and standard clinical criteria often miss low‑level disease. Molecular residual diseas…